Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
information fournie par Boursorama CP 15/10/2020 à 08:30
Ajouter Boursorama à vos sources

Strasbourg, France and Lund, Sweden - October 15, 2020 - 08:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce that they will be presenting a poster on BT-001 at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting. The congress will be held virtually from November 9 to 14, 2020.

BT-001 is an optimized oncolytic virus (OV) being co-developed by BioInvent and Transgene.

.../...

Valeurs associées

TRANSGENE
0,8540 EUR Euronext Paris -0,12%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
100,01 0,00%
HAFFNER ENERGY
0,637 +20,64%
CAC 40
8 154,91 +0,20%
2CRSI
29,36 +2,80%
SOITEC
152,05 -1,81%
Chargement...

Pages les plus populaires

L'offre BoursoBank